about
Injury associated with methamphetamine use: a review of the literature.Australian community pharmacy services: a survey of what people with chronic conditions and their carers use versus what they consider importantIs the pharmacy profession innovative enough?: meeting the needs of Australian residents with chronic conditions and their carers using the nominal group technique.Pharmacotherapy for treatment-resistant schizophrenia.Exploring an increased role for Australian community pharmacy in mental health professional service delivery: evaluation of the literature.The ideal healthcare: priorities of people with chronic conditions and their carers.A qualitative investigation into key cultural factors that support abstinence or responsible drinking amongst some Pacific youth living in New Zealand.The substances and choices scale (SACS)--the development and testing of a new alcohol and other drug screening and outcome measurement instrument for young people.Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.Burden of treatment for chronic illness: a concept analysis and review of the literature.Explicit versus implicit review to explore combination antipsychotic prescribing.Explicit review of risperidone long-acting injection prescribing practice.Implementation of a mental health medication management intervention in Australian community pharmacies: Facilitators and challenges.Australian mental health consumers and carers expect more health management information from community pharmacy.Management of children's fever by parents and caregivers: Practical measurement of functional health literacy.Consumer access to clozapine in Australia: how does this compare to New Zealand and the United Kingdom?Trends in antipsychotic prescribing in schizophrenia in Auckland.New Zealand community pharmacists' views of their roles in meeting medicine-related needs for people with mental illness.Self-management of chronic conditions in a rural and remote context.Clozapine and concomitant medications: Assessing the completeness and accuracy of medication records for people prescribed clozapine under shared care arrangements.Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013.Australian mental health consumers' and carers' experiences of community pharmacy service.Patterns of clozapine prescribing in a mental health service in New Zealand.Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health.Mental health consumer and caregiver perceptions of stigma in Australian community pharmacies.One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.Outcomes for schizophrenia patients with clozapine treatment: how good does it get?Evaluation of online training for the provision of opioid substitution treatment by community pharmacists in New Zealand.Barriers to, and incentives for, the transfer of opioid-dependent people on methadone maintenance treatment from secondary care to primary health care.Trust and safe spaces: mental health consumers' and carers' relationships with community pharmacy staff.Impact of audit and feedback on antipsychotic prescribing in schizophrenia.Initiation into methamphetamine use: qualitative findings from an exploration of first time use among a group of New Zealand users.Ethnic comparisons of antipsychotic use in schizophrenia.Determining what practising clinicians believe about long-acting injectable antipsychotic medication.Screening and brief interventions for alcohol: attitudes, knowledge and experience of community pharmacists in Auckland, New Zealand.When is a medicine unwanted, how is it disposed, and how might safe disposal be promoted? Insights from the Australian population.The impact of a person-centred community pharmacy mental health medication support service on consumer outcomes.Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers.Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.Caring for carers in community pharmacy.
P50
Q34567441-18503FC3-FEDD-46FA-8871-200BC8DB92EBQ34692203-88D405B8-AB7E-459E-B925-5F67639CB51BQ34806604-B6F9A5A2-1DE6-40FD-AAB3-9D52FD401082Q34879109-47DCF1CE-B6FC-4AD6-9B60-069E48E73DCFQ35853043-EA8A6F7E-3A62-4D10-8824-641C91E8EF0BQ35868401-DE50B1EC-287A-4F12-AFAC-CE1B4162D394Q36298747-F2AB916A-58C8-4ECA-AFDD-902B612D28D7Q36889010-786664D4-EDC0-4023-A0BC-B3BB638E9649Q37162884-55871F1B-6B68-4754-9560-77DAF6C9991BQ37333252-0576EAC7-9271-42B8-95F9-272FC219C106Q37578712-823DC5BE-73C1-4386-81D6-1A3D58D0EBC7Q37948911-53F8B911-F06E-4793-90EC-A4FAD3AA1A60Q38674556-348DBC8D-DA54-46F0-88DC-30C82E77A537Q38901999-2BFB91AB-8FD1-4DBA-AA69-0089FABFFE87Q39373789-02075D5B-7676-40D4-B355-D666BA0B2E53Q39628424-5ECA91CA-0D2E-4B56-AFBC-EB8FFA661CF4Q39756918-003591A8-FB74-4953-9A9E-4830B02CD6A3Q39789133-BFC94E91-258E-41B8-A870-19B19A610916Q40144163-A023AFFB-BC89-4FAE-A754-719103F5C93EQ40466435-9182006E-2B6A-462F-AC72-189A6F320B28Q40820070-0BBB5E6D-DF0A-4F3D-88EB-CC3C495F08FAQ42647559-A97BB769-149A-4E1A-A563-77691F0CACEEQ43043460-C19C4B51-D3F1-4F07-99D4-AA49EBF4BA5BQ43688690-541E8004-FBFC-4C0F-960D-1538FDC0077EQ43768698-EA764AA7-CCE2-4DB2-A78B-AEBCBB598C83Q43870857-FB821FA1-C6CE-4DA7-BE48-DD7F93FD9454Q44263856-260E9E9E-82DC-403F-B697-85EECACB653BQ44333964-FCE0B4B7-B12A-4A1C-A4A1-80B5A371C301Q44337793-FAAA2378-6B7A-49F8-A3D6-048DE3CDE3C4Q44354839-0946A5BA-C0E2-4D94-9887-87586B3A7D0AQ45789228-926BFA96-1709-4428-AA4A-E5ED187064EFQ46004334-DCD3C9ED-0700-4A0B-BD79-B933CF47A871Q46382373-62B3E2B1-A4FA-4998-A2BC-3B1C67AEB21DQ46391949-34DA85DD-EC8E-4A09-9046-BA55FBE00431Q46515575-432E61EE-86CD-4EB0-A699-ACB873558B66Q47573179-5B741B15-BEAF-422A-B3EA-5A1F81077971Q47677736-B8873130-1869-4466-B80F-B8401494F277Q50107034-4F66087F-0CF4-4C72-9CEF-DD886415178AQ50134375-8F19A87E-0BBC-4BBA-9887-70D618D0B42DQ50144255-7D2145E6-1192-4307-868F-330A4B6BAE41
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0001-9755-674X
@en
name
Amanda J. Wheeler
@ast
Amanda J. Wheeler
@en
Amanda J. Wheeler
@es
Amanda J. Wheeler
@nl
type
label
Amanda J. Wheeler
@ast
Amanda J. Wheeler
@en
Amanda J. Wheeler
@es
Amanda J. Wheeler
@nl
altLabel
A Wheeler
@en
prefLabel
Amanda J. Wheeler
@ast
Amanda J. Wheeler
@en
Amanda J. Wheeler
@es
Amanda J. Wheeler
@nl
P106
P1153
56692252900
9843898900
P21
P31
P496
0000-0001-9755-674X